OSE Immunotherapeutics SA (Euronext: OSE) and the FoRT Foundation announced completion of patient enrollment in a Phase 2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE